Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
INJECTION
**RECOMMENDED DOSE:** **Injection:** **Usual Adult and Adolescent Dose:** Antiemetic; or Antivertigo agent – Intramuscular, 50 mg repeated every four hours as needed. Intravenous, 50 mg in 10 mL of 0.9% sodium chloride injection, administered slowly over a period of at least two minutes, repeated every four hours as needed. **Usual Pediatric Dose: Antiemetic; or Antivertigo agent** – Intramuscular, 1.25 mg per kg of body weight or 37.5 mg per square meter of body surface, every six hours as needed, not to exceed 300 mg per day. Intravenous, 1.25 mg per kg of body weight or 37.5 mg per square meter of body surface, in 10 ml of 0.9% sodium chloride injection, administered slowly over a period of at least two minutes, every six hours as needed, not to exceed 300 mg per day. Note: Premature and full-term neonates – Use is not recommended. **Usual Geriatric Dose:** See Usual Adult and Adolescent Dose. Note: Geriatric patients may be more sensitive to the effects of the usual adult dose. As this preparation contains benzyl alcohol, its use should be avoided in children under two years of age. Not to be used in neonates. **ROUTE OF ADMINISTRATION:** Injection: For I.M. and I.V. injection
INTRAVENOUS, INTRAMUSCULAR
Medical Information
**INDICATIONS:** Prevention and relief of motion sickness, treatment of vertigo, nausea or vomiting associated with electroshock therapy, anaesthesia and surgery; labirinthine disturbances and radiation sickness.
**CONTRAINDICATIONS:** Dimenhydrinate is contraindicated in patients known to be allergic to this drug.
A04AD
其它镇吐药
Manufacturer Information
DUOPHARMA (SINGAPORE) PTE. LTD.
DUOPHARMA (M) SDN BHD
Active Ingredients
Documents
Package Inserts
Votmine Inj_PI_Proposed.pdf
Approved: January 20, 2021